Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1056/NEJMoa2033700 http://scihub22266oqcxt.onion/10.1056/NEJMoa2033700 33406353!7793608!33406353     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       N+Engl+J+Med 2021 ; 384 (7): 610-618 Nephropedia Template TP {{tp|p=33406353|t=2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults |pdf=|usr=}}{{33406353}} gab.com Text Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults JO: N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=33406353 #FOAvip BACKGROUND: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. The primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both. The trial was stopped early at 76% of its projected sample size because cases of Covid-19 in the trial region decreased considerably and steady enrollment of trial patients became virtually impossible. RESULTS: A total of 160 patients underwent randomization. In the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P = 0.03), with a relative risk reduction of 48%. A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse events were observed. CONCLUSIONS: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and Melinda Gates Foundation and the Fundacion INFANT Pandemic Fund; Direccion de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163.). Twit Text FOAVip Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults ????N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=33406353 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33406353 #FOAvip English Wikipedia <ref>{{Cite pmid|33406353}}</ref> Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults #MMPMID33406353 Libster R; Perez Marc G; Wappner D; Coviello S; Bianchi A; Braem V; Esteban I; Caballero MT; Wood C; Berrueta M; Rondan A; Lescano G; Cruz P; Ritou Y; Fernandez Vina V; Alvarez Paggi D; Esperante S; Ferreti A; Ofman G; Ciganda A; Rodriguez R; Lantos J; Valentini R; Itcovici N; Hintze A; Oyarvide ML; Etchegaray C; Neira A; Name I; Alfonso J; Lopez Castelo R; Caruso G; Rapelius S; Alvez F; Etchenique F; Dimase F; Alvarez D; Aranda SS; Sanchez Yanotti C; De Luca J; Jares Baglivo S; Laudanno S; Nowogrodzki F; Larrea R; Silveyra M; Leberzstein G; Debonis A; Molinos J; Gonzalez M; Perez E; Kreplak N; Pastor Arguello S; Gibbons L; Althabe F; Bergel E; Polack FP N Engl J Med 2021[Feb]; 384 (7): 610-618 PMID33406353show ga BACKGROUND: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. The primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both. The trial was stopped early at 76% of its projected sample size because cases of Covid-19 in the trial region decreased considerably and steady enrollment of trial patients became virtually impossible. RESULTS: A total of 160 patients underwent randomization. In the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P = 0.03), with a relative risk reduction of 48%. A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse events were observed. CONCLUSIONS: Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and Melinda Gates Foundation and the Fundacion INFANT Pandemic Fund; Direccion de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163.). |Aged[MESH] |Aged, 80 and over[MESH] |Blood Component Transfusion[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/complications/*therapy[MESH] |Disease Progression[MESH] |Double-Blind Method[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Immunoglobulin G/*blood[MESH] |Intention to Treat Analysis[MESH] |Kaplan-Meier Estimate[MESH] |Male[MESH] |Respiratory Insufficiency/etiology/*prevention & control[MESH] |SARS-CoV-2/*immunology[MESH]Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Ad(epmc).pdf DeepDyve Pubget Overpricing